policy,country,status,explanation,source
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Indonesia,PARTIAL,"Indonesia does not fully adopt the ICH CTD, but instead uses the ASEAN CTD (ACTD), a format derived from and closely aligned with the ICH CTD, for innovator pharmaceutical product registrations.[2]","https://ijprajournal.com/issue_dcp/A%20Review%20Article%20on%20the%20Common%20Technical%20Document%20CTD%20Regulatory%20Dossier.pdf,https://international-pharma.com/wp-content/uploads/2017/04/Comparison-of.pdf,https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m4-r4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-step-5_en.pdf,https://jpionline.org/storage/2023/12/IntJPharmInvestigation-14-1-1.pdf"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Indonesia,YES,"Indonesia provides a fully digital online submission portal for pharmaceutical product marketing authorization applications through the BPOM e-Registration system, where all applications must be submitted electronically.[2]","https://www.tilleke.com/insights/indonesia-updates-its-drug-advertising-guidelines/53/,https://clinchoice.co.jp/en/indonesia-regulatory-watch-a-primer-on-drug-registration-in-indonesia-august-2025/,https://baipharm.chemlinked.com/insights/indonesia-drug-registration-pathway,https://www.tilleke.com/insights/indonesia-updates-its-drug-advertising-guidelines/27/,https://credevo.com/articles/2021/05/25/drug-registration-process-in-indonesia/"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Indonesia,YES,"Indonesia is legally required to accept GMP certificates from other ASEAN Member States for pharmaceutical manufacturers under the ASEAN Mutual Recognition Arrangement on GMP inspection, which obliges all AMS to recognize GMP certificates issued by ASEAN Listed Inspection Services.[3][4]","https://certease.com/gmp-certification-in-indonesia/,https://asean.org/wp-content/uploads/images/2013/economic/iai/ASEAN%20Cosmetics%20Directive%20CLMV%20Workshop%20Feb%202013.pdf,https://globalforum.diaglobal.org/issue/march-2021/harmonization-of-gmp-inspection-and-benefits-to-asean-economic-community/,https://www.ncbi.nlm.nih.gov/books/NBK555744/,https://insightof.id/frequently-asked-questions-good-manufacturing-practice-gmp-certificate-for-cosmetics/"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Indonesia,YES,"Indonesia accepts stability data submission at 25°C/60% RH for pharmaceutical products, provided it is supported by long-term and accelerated stability studies in accordance with BPOM guidelines and ASEAN standards[5][2].","https://www.permitindo.com/news/bpom-health-supplement-stability-testing,https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf,https://foodcomplianceinternational.com/industry-insight/news/5384-bpom-issues-guidelines-for-stability-testing-of-health-supplements,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf,https://www.artixio.com/post/nadfc-bpom-regulation-of-pharmaceuticals-in-indonesia"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Indonesia,YES,"Indonesia allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing by adopting ASEAN guidelines, which explicitly permit these approaches for reduced testing schedules.[2][3]","https://www.permitindo.com/news/bpom-health-supplement-stability-testing,https://asean.org/wp-content/uploads/2017/09/ASEAN-Guidelines-on-Stability-and-Shelf-Life-TM-V1.0-with-disclaimer.pdf,https://foodcomplianceinternational.com/industry-insight/news/5384-bpom-issues-guidelines-for-stability-testing-of-health-supplements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1d-bracketing-and-matrixing-designs-stability-testing-new-drug-substances-and-products,https://food.chemlinked.com/database/view/5830"
Requires halal certification for pharmaceutical products.,Indonesia,YES,"Indonesia requires halal certification for pharmaceutical products, including medicines, supplements, and traditional remedies, under the Halal Product Assurance Law, with deadlines for compliance applying to over-the-counter and traditional drugs by 2026–2029[1][2][3].","https://emerhub.com/indonesia/halal-certification-in-indonesia/,https://emerhub.com/indonesia/understanding-the-process-and-requirements-of-indonesia-halal-certification/,https://indonesia.incorp.asia/blogs/halal-certification-procedure-2025/,https://apps.fas.usda.gov/newgainapi/api/Report/DownloadReportByFileName?fileName=Indonesia+Confirms+Extension+for+Mandatory+Halal+Certification+for+Imported+Food+and+Beverage+Products+and+Annulment+of+Apostille+Requirement_Jakarta_Indonesia_ID2024-0039,https://andamanmed.com/indonesia-implementation-of-halal-product-assurance-for-medical-devices-circulating-in-indonesia/"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Indonesia,NO,"Indonesia specifically mandates a red circle with the letter 'K' for prescription-only pharmaceutical products, not a plain 'red dot' symbol, according to BPOM regulations[1].","https://www.artixio.com/post/nadfc-bpom-regulation-of-pharmaceuticals-in-indonesia,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://www.visiott.com/blog/indonesia-pharmaceutical-track-and-trace-regulation/,https://core.ac.uk/download/pdf/159073290.pdf,https://www.freyrsolutions.com/blog/understanding-indonesias-new-labeling-regulations-for-natural-medicines-and-health-supplements"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Indonesia,PARTIAL,"Indonesia targets a six-month (approximately 130 working days) approval timeline only for priority drugs (orphan, pandemic, public health), while regular drugs take up to 150–300 working days, so the sub-six-month goal is not universal for all pharmaceutical products.[5][1][3]","https://www.pacificbridgemedical.com/publication/indonesias-national-agency-of-drug-and-food-control-bpom/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/,https://credevo.com/articles/2021/05/25/drug-registration-process-in-indonesia/,https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region,https://www.artixio.com/post/nadfc-bpom-regulation-of-pharmaceuticals-in-indonesia"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Indonesia,UNKNOWN,"Current evidence confirms Indonesia has antimicrobial stewardship and hospital antibiotic control programs, but there is no clear documentation of explicit hospital-only distribution restrictions for specific antimicrobial classes in the publicly available sources examined.","https://pmc.ncbi.nlm.nih.gov/articles/PMC9985506/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9195390/,https://japer.in/storage/files/article/4362fdc1-c981-4c8b-ae2e-b1b37b545dac-W5VwXUayM9b60sIZ/japer-vol-12-iss-4-19-26-8066.pdf,https://www.hsfkramer.com/notes/indonesia/2021-04/new-foreign-investment-rules-in-indonesias-healthcare-and-pharmaceutical-sectors,https://www.tropicalmedicine.ox.ac.uk/news/indonesia-faces-gaps-in-hospital-antibiotic-programmes-amid-fight-against-antimicrobial-resistance-study-by-universitas-indonesia-and-oucru-indonesia-finds"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Indonesia,YES,"Indonesia publishes national antimicrobial resistance (AMR) surveillance data, with recent efforts including a 2024-2025 national AMR survey of bloodstream infections and public releases of monitoring and evaluation outcomes from its National Action Plan for AMR control.[1][3][5]","https://www.who.int/indonesia/news/detail/13-02-2025-indonesia-launches-groundbreaking-national-amr-survey-on-bloodstream-infections,https://www.flemingfund.org/app/uploads/59f148b0482cda160087e29b9a5a21a0.pdf,https://www.fao.org/indonesia/news/detail/evaluation-of-the-2020-2024-nap-amr--positive-results-in-antimicrobial-resistance-control/en,https://ghsindex.org/wp-content/uploads/2021/12/Indonesia.pdf,https://www.who.int/indonesia/news/detail/03-09-2024-evaluation-of-ran-pra-2020-2024--control-of-antimicrobial-resistance-achieves-positive-results"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Vietnam,PARTIAL,"Vietnam requires pharmaceutical product registration dossiers to follow the ACTD (Asian Common Technical Dossier) format, but if ACTD arrangement is not feasible, it allows submission in ICH CTD format for innovator drugs and certain biologics[3][1][2].","https://dohapharma.com/pharmaceuticals/,https://international-pharma.com/wp-content/uploads/2017/04/Comparison-of.pdf,https://ijsrm.humanjournals.com/wp-content/uploads/2022/03/6.RamaKishore-E-G-Ravi-Shankar-N-Chagi-Venkatesh-S-B-Puranik.pdf,https://globallawexperts.com/drug-registration-process-in-vietnam-part-i-guide-for-foreign-companies-2025/,https://www.tilleke.com/insights/vietnam-issues-new-regulations-on-drug-registration/7/"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Vietnam,YES,"Vietnam provides a fully digital online submission portal for pharmaceutical product marketing authorization applications through the online public service portal of the Drug Administration Department (https://dav.gov.vn), as confirmed in recent 2025 regulatory guides.[2][5]","https://www.artixio.com/post/pharmaceutical-regulations-and-registration-in-vietnam,https://globalreferral.group/drug-registration-in-vietnam-guide-for-foreign-companies-p2/,https://www.tilleke.com/insights/vietnam-issues-new-regulations-on-drug-registration/7/,https://www.vietnam-briefing.com/news/vietnams-amended-pharmaceutical-law-navigating-the-key-changes.html/,https://hmlf.vn/business-sectors/healthcare/drug-registration-process-vietnam-guide-foreign-companies-2025-2/"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Vietnam,NO,"Vietnam does not have a legal requirement to automatically accept another ASEAN Member State’s (AMS) cGMP certificate for pharmaceutical manufacturers; instead, Vietnam recognizes certain international GMP standards (WHO-GMP, EU-GMP, PIC/S-GMP, Japan-GMP, US-cGMP), and may require its own review or inspection of foreign manufacturers, even if an AMS cGMP certificate is provided.[5][2]","http://vietnamlawmagazine.vn/cosmetic-producers-must-meet-cgmp-asean-standards-5253.html,https://www.pacificbridgemedical.com/news-brief/new-gmp-requirements-for-pharmaceutical-manufacturers-in-vietnam/,https://longphanpmt.com/en/cosmetics-factory-standards-meet-cgmp-standards/,https://www.hsa.gov.sg/docs/default-source/hprg/regulatory-updates/update-on-asean-mra-gmp.PDF,https://hmlf.vn/uncategorized/drug-registration-process-vietnam-guide-foreign-companies-2025/"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Vietnam,NO,"Vietnam, as a Zone IV country, requires long-term stability data at 30°C/75% RH (or 30°C/65% RH), not at 25°C/60% RH, for pharmaceutical product registration; 25°C/60% RH data is not generally accepted except for markets in cooler zones or under special justifications.[1][4]","https://www.pharmoutsourcing.com/Featured-Articles/37672-Regulatory-Strategy-for-Long-Term-Stability-Conditions-to-Support-Submission-in-Zone-IV-Countries/,https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf,https://www.tilleke.com/insights/vietnam-issues-new-regulations-on-drug-registration/,https://iris.who.int/bitstream/10665/72914/1/18_2_2004,https://clinregs.niaid.nih.gov/sites/default/files/documents/vietnam/BioTestReq_GoogleTranslation.pdf"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Vietnam,NO,"Vietnamese regulations do not explicitly allow bracketing and matrixing study designs for pharmaceutical stability testing; recent guidelines and registration circulars do not reference ICH Q1D or these reduced designs, and require testing according to pharmacopoeia standards and complete stability data in line with national requirements[1][5].","https://www.tilleke.com/insights/vietnam-updates-guidelines-on-drug-quality-standards-testing-and-noncompliance/,https://www.ema.europa.eu/en/ich-q1d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products-scientific-guideline,https://clinregs.niaid.nih.gov/sites/default/files/documents/vietnam/BioTestReq_GoogleTranslation.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://clinregs.niaid.nih.gov/sites/default/files/documents/vietnam/DrugRgstrtn_GoogleTranslation.pdf"
Requires halal certification for pharmaceutical products.,Vietnam,NO,"Vietnam does not require halal certification for pharmaceutical products by default; it is pursued voluntarily by companies primarily for export to halal markets and international buyers, not mandated by Vietnamese law.[1][3][4][5]","https://vietnamnews.vn/economy/1689525/local-herbal-company-becomes-halal-certified.html,https://www.tilleke.com/insights/new-regulations-on-drug-registration-in-vietnam/21/,https://www.halaltimes.com/vietnams-halal-products-take-center-stage-in-malaysia/,https://www.halaltimes.com/vietnam-pm-pushes-for-halal-expansion/,https://www.vietnam-briefing.com/news/vietnam-strategic-exports-push-into-the-middle-east-halal-market.html/"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Vietnam,NO,"Vietnamese regulations on pharmaceutical labeling, including the latest amendments effective January 2024, do not mandate the use of a 'red dot' symbol to indicate prescription-only drugs; the regulations focus on linguistic requirements, batch identification, and clarity, but do not specify a color-coded or symbolic system for prescription status.[1][5]","https://www.vietnam-briefing.com/doing-business-guide/vietnam/sector-insights/vietnam-updates-regulations-on-pharmaceutical-product-labeling,https://chicagounbound.uchicago.edu/cgi/viewcontent.cgi?article=2753&context=law_and_economics,https://vivabcs.com.vn/resources/representative-office/pharmacy-business-establish-representative-office/,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://clinregs.niaid.nih.gov/sites/default/files/documents/vietnam/MedLabel_GoogleTranslation.pdf"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Vietnam,NO,"Vietnam does not target an average MA approval timeline of six months or less; typical approval timelines for pharmaceutical products are reported as 14–22 months for generics and similarly extended for other categories, with no evidence of a six-month target.[1][3]","https://credevo.com/articles/2021/01/15/vietnam-generic-drug-registration-process/,https://pharmaboardroom.com/legal-reports/the-pharma-legal-handbook-vietnam/,https://www.rginsight.com/registration-of-drug-product-in-vietnam-2025,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/,https://patentpanorama.com/blogs/vietnams-new-regulations-on-drug-regulation"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Vietnam,PARTIAL,"Vietnam allows certain AM drugs for special treatment to be distributed only to specific hospitals upon request, but generally does not impose broad hospital-only distribution restrictions for antimicrobial classes; most restrictions focus on prescription-only dispensation and regulatory control rather than exclusive hospital channels[4][1].","https://www.tandfonline.com/doi/full/10.1080/09581596.2024.2303421,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019242/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9948497/,https://www.tilleke.com/sites/default/files/2017_Feb_Marketing_Distribution_Drugs_Vietnam.pdf,https://peercommunityjournal.org/item/10_24072_pcjournal_512/"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Vietnam,YES,"Vietnam publishes national antimicrobial resistance (AMR) surveillance data through a formal surveillance system, mandated by national policy and supported by the Ministry of Health, which gathers and reports standardized AMR data from hospital laboratories across the country[2][3][4].","https://archive.cdc.gov/www_cdc_gov/drugresistance/solutions-initiative/stories/tracking-resistance-in-vietnam.html,https://ghsindex.org/wp-content/uploads/2021/12/Vietnam.pdf,https://pubmed.ncbi.nlm.nih.gov/33971969/,https://pmc.ncbi.nlm.nih.gov/articles/PMC10809436/,https://amr.cgiar.org/case-study/situation-analysis-antimicrobial-resistance-surveillance-and-control-vietnam"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Laos,PARTIAL,"Laos generally accepts the ASEAN Common Technical Document (ACTD) format for pharmaceutical product registrations, but the ICH CTD format is also acceptable in some ASEAN countries; however, there is no clear, explicit evidence that Laos mandates or fully aligns with the ICH CTD, so submissions using ICH CTD formatting may be possible but are not formally required as in ICH member regions.[3][5]","https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://api.pageplace.de/preview/DT0400.9781420081831_A37765401/preview-9781420081831_A37765401.pdf,https://www.productlifegroup.com/extension-us-eu-dossier-asean-countries-cmc-perspective/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m4-r4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-step-5_en.pdf,https://international-pharma.com/wp-content/uploads/2017/04/Comparison-of.pdf"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Laos,YES,"Laos provides a fully digital online submission portal for pharmaceutical product marketing authorization applications through the LAOREG system, which allows online applications and assessment for marketing authorization.","https://www.artixio.com/qatar/pharma/regulatory-affairs,https://pmc.ncbi.nlm.nih.gov/articles/PMC8483304/,https://www.laotradeportal.gov.la/en-gb/site/display/41,https://www.iqvia.com/-/media/iqvia/pdfs/asia-pacific/apac-insight-magazine/iqvia-apac-insight-issue10-vf.pdf,https://laoreg.online/adm/index.php"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Laos,YES,"Laos is a signatory to the ASEAN Sectoral Mutual Recognition Arrangement (MRA) on GMP Inspection, which facilitates acceptance of GMP certificates issued by regulatory authorities of other ASEAN Member States for pharmaceutical manufacturers as part of regulatory harmonization within the region[1][3][5].","https://ipq.org/asean-effort-progressing-on-cmcgmp-harmonization-but-differences-remain/,https://asean.org/wp-content/uploads/images/2013/economic/iai/ASEAN%20Cosmetics%20Directive%20CLMV%20Workshop%20Feb%202013.pdf,https://globalforum.diaglobal.org/issue/september-2018/regulatory-harmonization-and-recognition-continue-in-asean/,https://jicwels.or.jp/files/CountryReports/medicine/2012(H24)_%E5%BF%85%E9%A0%88%E5%8C%BB%E8%96%AC%E5%93%81%E8%A3%BD%E9%80%A0%E5%93%81%E8%B3%AA%E7%AE%A1%E7%90%86%EF%BC%88GMP%EF%BC%89.pdf,http://www.fdd.gov.la/fullnews_en.php?newsID=94"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Laos,NO,"Laos is classified as a WHO Climatic Zone IVa country, which requires stability data at 30°C/65% RH or higher; data at 25°C/60% RH is not accepted for registration unless specifically allowed by the national authority, and there is no evidence Laos permits this substitution.[3][5]","https://humiditycontrol.com/blog/what-is-stability-testing/,https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf,https://www.pharmoutsourcing.com/Featured-Articles/37672-Regulatory-Strategy-for-Long-Term-Stability-Conditions-to-Support-Submission-in-Zone-IV-Countries/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf,http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Laos,UNKNOWN,"There is no explicit information in the available sources indicating whether Laos specifically allows or prohibits the use of bracketing and matrixing designs in pharmaceutical product stability testing; guidance on stability testing in Laos has not been made public as of August 2025, and the country's recent regulations focus on biopharmaceutical products rather than general stability study protocols.[5]","https://humiditycontrol.com/blog/what-is-stability-testing/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://siip.ac.in/wp-content/uploads/2021/04/stability-testing.pdf,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1d-bracketing-and-matrixing-designs-stability-testing-new-drug-substances-and-products,https://www.tilleke.com/insights/laos-new-regulation-on-biopharmaceuticals-gene-therapy-and-stem-cells/"
Requires halal certification for pharmaceutical products.,Laos,PARTIAL,"Halal certification is available and encouraged for pharmaceutical products in Laos but is not legally required; it remains a voluntary process to enhance market access and consumer trust, rather than a regulatory mandate.[1][3][4]","https://seasia.co/2025/08/02/laos-halal-market-a-promising-sector-for-investors-and-entrepreneurs,https://halalfoundation.org/insights/halal-pharmaceuticals-and-supplements-certification/,https://ic-halal.com/industries/pharma/,https://www.tilleke.com/insights/laos-requirements-businesses-importing-and-exporting-medicines-and-medical-productsdevices/19/,https://www.efpia.eu/media/412591/efpia-positionpaper-on-halal_final_5-dec-2018.pdf"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Laos,NO,"Laos does not specifically mandate a “red dot” symbol on prescription-only pharmaceuticals; labeling laws require special wording in red for dangerous drugs, but make no mention of a red dot symbol for prescription-only medicines[1].","https://www.laotradeportal.gov.la/en-gb/site/display/41,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,http://fdd.gov.la/download/contentfiles/2018-07-18_113527am_Regulation%20on%20Establishment%20on%20Export_Import%20Company.pdf,https://iris.who.int/bitstream/handle/10665/43080/9241592508.pdf?sequence=1,https://www.tilleke.com/insights/laos-implements-medical-device-registration-and-notification-requirements/70/"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Laos,YES,"Laos targets an average marketing authorization (MA) approval timeline of approximately six months, as the medicinal product registration process typically takes about six months once the application is confirmed and all documents are received.[1]","https://credevo.com/articles/2021/04/25/generic-drug-approval-process-in-laos/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/,https://www.tilleke.com/insights/laos-implements-medical-device-registration-and-notification-requirements/26/,https://www.youtube.com/watch?v=AtUChEfkokY,https://www.ijdra.com/index.php/journal/article/download/158/77"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Laos,NO,"There is no evidence from available sources that Laos imposes hospital-only distribution restrictions on certain classes of antimicrobial pharmaceuticals; instead, challenges in Laos focus on limited access, availability, and antibiotic stewardship, rather than formal restriction of certain antimicrobials to hospital settings.","https://pmc.ncbi.nlm.nih.gov/articles/PMC10801825/,https://pmc.ncbi.nlm.nih.gov/articles/PMC11411237/,https://pmc.ncbi.nlm.nih.gov/articles/PMC8638151/,https://www.ibanet.org/document?id=Healthcare-Survey-Responses-2024-Laos,https://wellcomeopenresearch.org/articles/9-183"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Laos,YES,"Laos publishes national AMR surveillance data: it has established a systematic national AMR surveillance system, shares surveillance data among hospitals, and reports data to international systems like WHO GLASS, with recent initiatives supporting regular data collection and public health reporting.","https://pmc.ncbi.nlm.nih.gov/articles/PMC8638151/,https://ghsindex.org/wp-content/uploads/2021/12/Laos.pdf,https://www.who.int/laos/our-work/tracking-and-combating-antimicrobial-resistance,https://www.ivi.int/who-we-are/ivi-and-lao-peoples-democratic-republic/,https://captura.ivi.int/2025/06/03/strengthening-antimicrobial-use-amu-monitoring/"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Brunei,PARTIAL,"Brunei accepts dossiers prepared according to ICH guidelines and permits CTD format for innovator pharmaceutical product registrations, although its national system is also aligned with the ASEAN Common Technical Dossier (ACTD), and some country-specific requirements may apply[1][5].","https://www.ijdra.com/index.php/journal/article/download/410/209,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m4-r4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-step-5_en.pdf,https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://ijprajournal.com/issue_dcp/Significance%20of%20Common%20Technical%20Document%20in%20Pharmacy%20Regulation%20%20A%20Review.pdf,https://journalforclinicalstudies.com/wp-content/uploads/2015/02/09.-Comparison-of-Marketing-Authorisation.pdf"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Brunei,NO,Brunei does not provide a fully digital online submission portal for pharmaceutical product marketing authorization; applications must be submitted electronically on a CD and delivered physically to the Department of Pharmaceutical Services.[2],"https://www.ijdra.com/index.php/journal/article/view/410,https://www.scribd.com/document/611930840/Guide-to-Application-for-Registration-of-Medicinal-Products-4th-Editi,https://www.biopharminternational.com/view/bruneis-potential-pharmaceutical-market-growth-0,https://www.ardms.org/maintain-certification/registrant-support/statusverification/,https://business.mofe.gov.bn/SitePages/business-licenses-and-approvals.aspx"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Brunei,UNKNOWN,Available sources do not confirm that Brunei legally requires acceptance of another AMS's cGMP certificate for pharmaceutical manufacturers; no direct evidence of a mandatory requirement is found.,"https://asean.org/wp-content/uploads/AVG-Revision-2-endorsed-31PPWG.pdf,https://www.aseanconsumer.org/file/post_image/BRUNEI-FINAL%20REPORT%20-%20Revised%2018Jun2014.pdf,https://www.pacificbridgemedical.com/regulation/asean-medical-device-pharmaceutical-regulations/,https://www.giz.de/de/downloads/giz2015-en-Laos_and_the_ASEAN_Economic_Community_-_8__factsheets.pdf,https://www.trade.gov/country-commercial-guides/brunei-standards-trade"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Brunei,NO,"Brunei, as part of ASEAN and a Zone IV country, requires long-term stability data at 30°C/65% RH for pharmaceutical submissions; data only at 25°C/60% RH, even with accelerated studies, does not fulfill their requirements.[3][4]","https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf,https://www.pharmoutsourcing.com/Featured-Articles/37672-Regulatory-Strategy-for-Long-Term-Stability-Conditions-to-Support-Submission-in-Zone-IV-Countries/,https://iris.who.int/bitstream/10665/72914/1/18_2_2004,https://humiditycontrol.com/blog/what-is-stability-testing/"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Brunei,UNKNOWN,"There is no explicit information in the available sources confirming whether Brunei specifically allows bracketing and matrixing study designs in pharmaceutical stability testing; Brunei's regulations may be influenced by international ICH guidelines, but direct confirmation is absent.","https://humiditycontrol.com/blog/what-is-stability-testing/,https://www.ema.europa.eu/en/ich-q1d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products-scientific-guideline,https://farabipharma.ir/wp-content/uploads/2017/07/Handbook-of-Stability-Testing-in-Pharmaceutical-Development-Regulations-Methodologies-and-Best-.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://www.labmanager.com/stability-testing-of-pharmaceuticals-procedures-and-best-practices-33944"
Requires halal certification for pharmaceutical products.,Brunei,NO,"Brunei does not require halal certification for pharmaceutical products; the certification is compulsory only for food businesses, while non-food items such as pharmaceuticals are exempt unless they are oral or consumed products[2].","https://halalfocus.com/brunei-unveils-halal-pharma-guidelines/,http://news.xinhuanet.com/english/2017-07/14/c_136444795.htm,https://borneobulletinyearbook.com.bn/halal/,https://certease.com/halal-certification-in-brunei/,https://www.halalrc.org/images/Research%20Material/Report/GUIDELINE%20FOR%20HALAL%20CERTIFICATION.pdf"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Brunei,NO,"No evidence was found in Brunei’s official pharmacovigilance or medicines regulations mandating a 'red dot' symbol for prescription-only pharmaceutical products; such a requirement is specified in Indonesia, not Brunei.[1][5][3]","https://moh.gov.bn/wp-content/uploads/2024/10/Brunei-Darussalam-Pharmacovigilance-Guidelines-31.7.18.pdf,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://www.artixio.com/post/nadfc-bpom-regulation-of-pharmaceuticals-in-indonesia,https://www.annualreports.com/HostedData/AnnualReportArchive/d/NASDAQ_DCPH_2020.pdf,https://www.agc.gov.bn/AGC%20Images/LAWS/ACT_PDF/M/CHAPTER%20285%20RG%201.pdf"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Brunei,NO,"Brunei's average marketing authorization (MA) approval timeline for pharmaceutical products is about 286 days (over 9 months), which exceeds a six-month target[1][5].","https://credevo.com/articles/2021/03/25/brunei-generic-drug-registration-process/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/,https://moh.gov.bn/wp-content/uploads/2024/10/Brunei-Darussalam-Pharmacovigilance-Guidelines-31.7.18.pdf,https://www.marks-clerk.com/insights/latest-insights/102jw4m-extending-patent-term-in-southeast-asia/,https://www.ijdra.com/index.php/journal/article/download/410/209"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Brunei,NO,Brunei classifies all antimicrobials as prescription-only medicines but there is no evidence of specific hospital-only distribution restrictions for certain antimicrobial classes; the focus is on prescription control rather than hospital-only access.[3][5],"https://asean.org/wp-content/uploads/2023/02/Rapid-Assessment-of-the-Regulatory-Measures-in-Combating-Antimicrobial-Resistance-AMR-in-the-ASEAN-Region_-Feb-2023-OK-1.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC11795752/,https://ghsindex.org/wp-content/uploads/2021/12/Brunei.pdf,https://documents1.worldbank.org/curated/en/323311493396993758/pdf/final-report.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC10843100/"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Brunei,PARTIAL,"Brunei collects AMR and antimicrobial use data within the public health sector and through importation records, but does not publish comprehensive national AMR surveillance data covering both human and veterinary pharmaceutical products, with existing data having incomplete coverage and surveillance systems not fully developed.[1][2][3]","https://ghsindex.org/wp-content/uploads/2021/12/Brunei.pdf,https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0297921,https://asean.org/wp-content/uploads/2023/02/Rapid-Assessment-of-the-Regulatory-Measures-in-Combating-Antimicrobial-Resistance-AMR-in-the-ASEAN-Region_-Feb-2023-OK-1.pdf,https://apps.who.int/iris/bitstream/handle/10665/332081/9789240005587-eng.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC10843100/"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Thailand,YES,"Thailand accepts the ICH Common Technical Document (CTD) format for innovator pharmaceutical product registrations, as the Thai FDA requires documentation in accordance with both the ASEAN Common Technical Dossier (ACTD) and the ICH CTD formats for drug registration.","https://www.freyrsolutions.com/blog/thailand-moving-forward-to-ectd-submissions,https://ijprajournal.com/issue_dcp/A%20Review%20Article%20on%20the%20Common%20Technical%20Document%20CTD%20Regulatory%20Dossier.pdf,https://www.chameleon-pharma.com/the-pillars-of-control-approaching-thailands-national-drug-framework-and-otc-rx-drug-registration-process/,https://international-pharma.com/wp-content/uploads/2017/04/Comparison-of.pdf,https://www.artixio.com/post/thailand-fda-regulations-for-pharmaceutical-registration"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Thailand,PARTIAL,"Thailand provides the Skynet E-Submission System, an online portal for pharmaceutical product marketing authorization applications, but full online access is generally limited to Thai citizens and requires prior approval via the E-Consult system, with foreign applicants needing to appoint a local representative to use the system.[2][4]","https://ijsrm.humanjournals.com/wp-content/uploads/2022/03/5.RamaKishore-E-G-Ravi-Shankar-N-Chagi-Venkatesh-S-B-Puranik.pdf,https://clinregs.niaid.nih.gov/country/thailand,https://baipharm.chemlinked.com/news/thai-fda-expedites-drug-import-via-digital-channel,https://clinregs.niaid.nih.gov/country/thailand/united-states,https://en.fda.moph.go.th/other/category/cat-mandatory-reports"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Thailand,YES,"Thailand is legally obliged to accept and recognize another ASEAN Member State’s GMP Certificates and inspection reports issued by ASEAN Listed Inspection Services under the ASEAN Sectoral Mutual Recognition Arrangement (MRA) on GMP Inspection, which is binding on all ASEAN Member States including Thailand[2][4][5].","https://www.tilleke.com/insights/good-manufacturing-practices-thailand/,https://globalforum.diaglobal.org/issue/march-2021/harmonization-of-gmp-inspection-and-benefits-to-asean-economic-community/,https://globallawexperts.com/thailands-fda-proposes-amendments-to-streamline-gmp-certification-for-foreign-drug-manufacturers/,https://gabi-journal.net/a-review-of-international-initiatives-on-pharmaceutical-regulatory-reliance-and-recognition.html,https://apac-asia.com/images/achievements/pdf/6th/02-04.pdf"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Thailand,PARTIAL,"Thailand generally follows ASEAN stability guidelines, which accept 25°C/60% RH as a long-term stability testing condition, but data solely at 25°C/60% RH—even when supported by accelerated studies—may be rejected as 'less stressful' than the preferred 30°C/75% RH for Zone IVb (Thailand's climatic zone); additional justification or intermediate condition data may be required if significant changes are observed during accelerated testing[5][1].","https://www.artixio.com/post/thailand-fda-regulations-for-pharmaceutical-registration,https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf,http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf,https://asean.org/wp-content/uploads/2018/01/25PPWG-ANNEX-7-iv-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2.pdf"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Thailand,YES,"Thailand, as a member of ASEAN, allows bracketing and matrixing designs in pharmaceutical stability studies, as reflected in the ASEAN Guidelines on Stability Study and Shelf-Life, which Thailand follows for regulatory compliance[2].","https://www.artixio.com/post/thailand-fda-regulations-for-pharmaceutical-registration,https://asean.org/wp-content/uploads/2017/09/ASEAN-Guidelines-on-Stability-and-Shelf-Life-TM-V1.0-with-disclaimer.pdf,https://humiditycontrol.com/blog/what-is-stability-testing/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://siip.ac.in/wp-content/uploads/2021/04/stability-testing.pdf"
Requires halal certification for pharmaceutical products.,Thailand,NO,"Thailand does not require halal certification for pharmaceutical products as a regulatory mandate, but it does offer voluntary halal certification for pharmaceuticals, particularly for export and marketing purposes to Muslim consumers[3][4][5].","https://www.nationthailand.com/business/economy/40045799,https://unissa.edu.bn/journal/index.php/jhst/article/download/664/598,https://www.halaltimes.com/evolution-of-thai-halal-products-and-their-significance-in-the-usa/,https://halalfoundation.org/major-halal-certification-companies/,https://thailand.prd.go.th/en/content/category/detail/id/2078/iid/409724"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Thailand,PARTIAL,"Thailand appears to use a red dot marker to distinguish certain categories of medicines, including prescription-only and specially controlled medicines, but the sources reviewed do not establish a current, explicit legal mandate by the Thai government specifically requiring a 'red dot' on all prescription-only pharmaceutical product labels.[2]","https://www.artixio.com/post/medical-device-regulations-registration-process-in-thailand,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://andamanmed.com/thailand-draft-criteria-methods-and-conditions-on-labeling-and-documentation-ifu-for-medical-devices/,https://msh.org/wp-content/uploads/2025/07/MTP-Malaria-online.pdf,https://ota.fas.org/reports/9321.pdf"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Thailand,NO,"Thailand does not target an average MA approval timeline of six months or less for pharmaceutical products; the registration process typically ranges from 6 months to 2 years depending on product type, with new drugs commonly requiring 220–280 working days (i.e., often more than six months)[1][3].","https://www.artixio.com/post/thailand-fda-regulations-for-pharmaceutical-registration,https://www.tilleke.com/insights/thailand-prepares-to-renew-drug-marketing-authorizations-as-first-expiration-nears/23/,https://credevo.com/articles/2023/10/05/new-drug-registration-process-in-thailand-a-guide-to-market-entry/,https://pmc.ncbi.nlm.nih.gov/articles/PMC7516132/,https://www.tilleke.com/insights/thailand-prepares-to-renew-drug-marketing-authorizations-as-first-expiration-nears/14/"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Thailand,NO,"Thailand does not impose hospital-only distribution restrictions for most antimicrobial pharmaceutical products; antibiotics are widely and legally available through retail pharmacies, often without prescription, except for a limited subset classified as 'specially controlled' drugs[2][3][5].","https://pmc.ncbi.nlm.nih.gov/articles/PMC8944558/,https://pmc.ncbi.nlm.nih.gov/articles/PMC5791780/,https://pmc.ncbi.nlm.nih.gov/articles/PMC8381094/,https://orca.cardiff.ac.uk/id/eprint/137072/1/2020SisiraDonsamakPhD.pdf,https://iris.who.int/bitstream/handle/10665/380437/9789290229971-eng.pdf?sequence=1&isAllowed=y"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Thailand,YES,"Thailand publishes national AMR surveillance data through systems like the National Antimicrobial Resistance Surveillance Thailand (NARST), with regular reports covering data related to pharmaceutical products and resistance trends across human health sectors.","https://figshare.com/articles/dataset/Antimicrobial-resistant_surveillance_reports_of_25_hospitals_in_Thailand_in_2022/22339933,https://rr-asia.woah.org/app/uploads/2020/03/thailand_thailands-national-strategic-plan-on-amr-2017-2021.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC8381094/,https://www.hitap.net/wp-content/uploads/2021/04/Booklet-AMR.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC10349292/"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Myanmar,NO,"Myanmar does not officially accept the ICH CTD format for innovator pharmaceutical product registrations; it is not listed among countries using this format, and ASEAN countries including Myanmar typically follow the ACTD format instead.[4][5]","https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m4-r4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-step-5_en.pdf,https://jgtps.com/admin/uploads/zhg3fT.pdf,https://www.ijdra.com/index.php/journal/article/download/510/264,https://www.ijdra.com/index.php/journal/article/download/442/222"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Myanmar,PARTIAL,"Myanmar has implemented an electronic submission system for pharmaceutical product registration and related import licensing, but available guidelines and notifications indicate that full digitalization is limited to certain steps (such as e-submission and online fee payments), while some documentation and initial submissions may still require in-person handling, especially for new marketing authorization applications[1][3][5].","https://www.myanmartradeportal.gov.mm/attachment/274/download,https://www.questjournals.org/jrbm/papers/vol10-issue4/Ser-3/D10042733.pdf,https://lic-public.wto.org/en/legislations/1165,https://www.southuniversity.edu/savannah/physician-assistant-ms,https://lic-public.wto.org/en/product-categories/569/procedure"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Myanmar,YES,"Myanmar is required to legally accept another ASEAN Member State's cGMP certificate for pharmaceutical manufacturers under the ASEAN Sectoral Mutual Recognition Arrangement (MRA) for GMP inspection, provided the certificate is issued by a Listed Inspection Service of an AMS[4].","https://asean.org/wp-content/uploads/2022/12/ASEAN-Pharmaceutical-Regulatory-Policy-Sample-Print-REV-20122022-.pdf,https://asean.org/wp-content/uploads/images/2013/economic/iai/ASEAN%20Cosmetics%20Directive%20CLMV%20Workshop%20Feb%202013.pdf,https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f636695447956123279&type=4,https://asean.org/wp-content/uploads/images/archive/documents/Agreement%20on%20MRA%20for%20GMP%20Pharmaceutical.pdf,https://www.pacificbridgemedical.com/regulation/asean-medical-device-pharmaceutical-regulations/"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Myanmar,UNKNOWN,There is no explicit information in the search results confirming whether Myanmar permits submission of stability data at 25°C/60% RH supported only by accelerated studies; the results summarize general ICH guidelines but do not describe Myanmar's specific requirements.,"https://humiditycontrol.com/blog/what-is-stability-testing/,https://pharm-community.com/wp-content/uploads/wpforo/default_attachments/1484853135-draft-who-stability-guideline-rev-3-sept-2008.pdf,https://siip.ac.in/wp-content/uploads/2021/04/stability-testing.pdf,https://www.npra.gov.my/easyarticles/images/users/1057/GUIDELINE-FOR-STABILITY-DATA.pdf,https://www.labmanager.com/stability-testing-of-pharmaceuticals-procedures-and-best-practices-33944"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Myanmar,UNKNOWN,There is no explicit information in the available search results regarding whether Myanmar specifically allows bracketing and matrixing study designs in pharmaceutical product stability testing.,"https://humiditycontrol.com/blog/what-is-stability-testing/,https://www.ema.europa.eu/en/ich-q1d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products-scientific-guideline,https://siip.ac.in/wp-content/uploads/2021/04/stability-testing.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://www.labmanager.com/stability-testing-of-pharmaceuticals-procedures-and-best-practices-33944"
Requires halal certification for pharmaceutical products.,Myanmar,NO,"Myanmar does not require halal certification for pharmaceutical products; halal certification is mainly relevant for food products, and the country lacks a national mandatory framework for pharmaceuticals.","https://halalfoundation.org/insights/halal-pharmaceuticals-and-supplements-certification/,https://www.efpia.eu/media/412591/efpia-positionpaper-on-halal_final_5-dec-2018.pdf,https://factocert.com/myanmar/halal-certification-in-myanmar/,https://www.aseanbriefing.com/news/asean-regulatory-brief-laos-investment-incentives-brunei-halal-certification-myanmar-livestock-exports/,https://seasia.co/2025/08/01/emerging-trends-in-myanmars-halal-food-market-opportunities-for-growth"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Myanmar,UNKNOWN,There is no direct evidence in the available sources confirming whether Myanmar mandates the use of a 'red dot' symbol on prescription-only pharmaceutical products.,"https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f636695447956123279&type=4,https://iris.who.int/bitstream/handle/10665/43080/9241592508.pdf?sequence=1,https://www.unodc.org/documents/southeastasiaandpacific/2010/12/ops-myanmar-ats/Myanmar_ATS_Report_2010_lowres.pdf,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://apps.who.int/iris/bitstream/handle/10665/326708/9789241513425-eng.pdf"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Myanmar,NO,"Myanmar does not target an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products; the current timeline is approximately 18-24 months, with possible reductions to 12-15 months according to recent reforms, but still over six months.[1]","https://www.questjournals.org/jrbm/papers/vol10-issue4/Ser-3/D10042733.pdf,https://www.sfamgroup.com/en/ma-pharmaceutical-medicines/,https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f636695447956123279&type=4,https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region,https://pharmexcil.com/uploads/countryreports/Myanmar.pdf"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Myanmar,NO,"There is no evidence that Myanmar imposes hospital-only distribution restrictions for certain classes of antimicrobial pharmaceutical products; antibiotics are widely available, including over-the-counter sales without prescription, and no national system restricts their distribution to hospitals only[1][2][4].","https://ghsindex.org/wp-content/uploads/2021/12/Myanmar.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC8167548/,https://steps-centre.org/wp-content/uploads/2022/12/Taking-Myanmars-AMR-National-Action-Plan-forward_November2022_2.pdf,https://researchonline.lshtm.ac.uk/id/eprint/4668293/1/2022_PHP_PhD_Khine%20Zaw_Y-sigs-photos-redacted.pdf,https://antimicrobialsinsociety.org/essential-reading/negotiating-authoritarian-law-and-disorder/"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Myanmar,PARTIAL,"Myanmar has a national AMR surveillance system and has published national AMR surveillance data as of 2017, reporting resistance rates in key pathogens, but there is no evidence of regular or recent publication of comprehensive AMR surveillance data specifically related to pharmaceutical products after that year[4][5].","https://solve.mit.edu/challenges/trinity-challenge-amr/solutions/85892,https://ghsindex.org/wp-content/uploads/2021/12/Myanmar.pdf,https://pubmed.ncbi.nlm.nih.gov/34070228/,https://journals.plos.org/plosone/article/file?id=10.1371%2Fjournal.pone.0273380&type=printable,https://pmc.ncbi.nlm.nih.gov/articles/PMC9387831/"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Philippines,YES,"The Philippines accepts the ICH Common Technical Document (CTD) format for innovator pharmaceutical product registrations, as the Philippines FDA allows submission in either the ICH CTD or ASEAN ACTD format for pharmaceutical registration.[3][4]","https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m4-r4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-step-5_en.pdf,https://www.pacificbridgemedical.com/publication/philippines-food-and-drug-administration-philippines-fda/,https://aapsopen.springeropen.com/articles/10.1186/s41120-024-00102-2,https://www.ijdra.com/index.php/journal/article/download/669/362"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Philippines,PARTIAL,"The Philippines requires electronic portal accounts for regulatory submissions, but while some steps (like application for License to Operate and communication) are supported online, there is no clear evidence of a fully digital online submission portal that encompasses the entire pharmaceutical marketing authorization process with end-to-end digital application and approval; certain procedures and documentation may still require physical or hybrid processes[5][1].","https://cruzmarcelo.com/philippine-department-of-health-issues-guidelines-for-the-registration-of-pharmaceutical-products-and-active-pharmaceutical-ingredients-intended-for-human-use/,https://www.dmp.no/en/approval-of-medicines/approval-and-follow-up-of-marketing-authorisation-ma/application-for-marketing-authorisation/submission-of-applications,https://www.pharmatomarket.com/the-philippines-announces-the-launch-of-verification-portal-for-licensed-establishments-and-registered-products-29-september-2020/,https://pmc.ncbi.nlm.nih.gov/articles/PMC11080122/,https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/philippines-drug-registration-and-approval-2/"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Philippines,YES,"The Philippines is legally required to accept and recognize another ASEAN Member State’s cGMP certificate or inspection report issued by an ASEAN Listed Inspection Service (LIS), in accordance with the ASEAN Mutual Recognition Arrangement (MRA) on GMP for finished pharmaceutical products[2][4].","https://factocert.com/gmp-certification-in-philippines-good-manufacture/,https://globalforum.diaglobal.org/issue/march-2021/harmonization-of-gmp-inspection-and-benefits-to-asean-economic-community/,https://factocert.com/process-of-gmp-certification-in-philippines/,http://www.fdd.gov.la/userfiles/files/FAQ-GMP%20(1).pdf,http://media.drugdu.com/latestinformation/procedures-and-requirements-of-gmp-certification-of-pharmaceutical-drugs-in-the-philippines.html"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Philippines,NO,"The Philippines, as part of ASEAN and a country in Climatic Zone IVb, requires long-term stability data at 30°C/75% RH—not 25°C/60% RH—because it is classified as a hot, very humid climate and does not permit 25°C/60% RH data submission for pharmaceutical products unless specifically justified; accelerated stability studies cannot substitute for this requirement.[5]","https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf,https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf,http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC11858995/,https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Philippines,YES,"The Philippines, as a member of ASEAN, follows the ASEAN Guideline on Stability Study of Drug Product, which permits the use of bracketing and matrixing in stability study designs if scientifically justified, in line with ICH recommendations.[5][4]","https://humiditycontrol.com/blog/what-is-stability-testing/,https://aapsopen.springeropen.com/articles/10.1186/s41120-023-00078-5,https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf"
Requires halal certification for pharmaceutical products.,Philippines,NO,"Halal certification for pharmaceutical products in the Philippines is voluntary rather than mandatory, as national regulations do not require it for domestic consumption.[2][5]","https://emerhub.com/philippines/how-to-get-halal-certification-in-the-philippines-a-guide-for-businesses/,https://apps.fas.usda.gov/newgainapi/api/Report/DownloadReportByFileName?fileName=Market+Brief+on+Halal+Products_Manila_Philippines_RP2023-0049.pdf,https://iso-certification.ph/the-ultimate-guide-to-halal-certification-in-the-philippines/,https://glenwood.ph/2023/02/webinar-philippine-halal-regulatory-requirements/,https://cosmetic.chemlinked.com/cosmepedia/asean-cosmetic-halal-certification-regulation"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Philippines,NO,Current Philippine drug labeling regulations do not specifically mandate the use of a 'red dot' symbol on prescription-only pharmaceutical products; labeling requirements focus instead on generics prominence and detailed information as outlined in Administrative Order No. 55 s. 1988[1].,"https://www.slideshare.net/slideshow/ra-55/45401812,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://www.fda.gov/food/hfp-constituent-updates/fda-revoke-authorization-use-red-no-3-food-and-ingested-drugs,https://www.guttmacher.org/sites/default/files/report_pdf/abortion-methodologies.pdf,https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Philippines,UNKNOWN,There is no explicit evidence in current search results indicating that the Philippines targets an average marketing authorization approval timeline of six months or less for pharmaceutical products.,"https://pharmexcil.com/uploads/countryreports/Philippines.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC7516132/,https://cruzmarcelo.com/philippine-department-of-health-issues-guidelines-for-the-registration-of-pharmaceutical-products-and-active-pharmaceutical-ingredients-intended-for-human-use/,https://www.ijdra.com/index.php/journal/article/download/244/137,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Philippines,PARTIAL,"The Philippines has policies restricting the use and prescribing of certain antimicrobials within health facilities through Antimicrobial Stewardship Programs (AMS), but there is no clear evidence of a nationwide legal restriction limiting the distribution of specific AM products exclusively to hospitals; enforcement primarily relies on hospital-level policies, not a hospital-only distribution mandate.[2][4]","https://pmc.ncbi.nlm.nih.gov/articles/PMC11879887/,https://pubmed.ncbi.nlm.nih.gov/39399371/,https://pmc.ncbi.nlm.nih.gov/articles/PMC12188270/,https://asean.org/wp-content/uploads/2023/02/Rapid-Assessment-of-the-Regulatory-Measures-in-Combating-Antimicrobial-Resistance-AMR-in-the-ASEAN-Region_-Feb-2023-OK-1.pdf,https://documents1.worldbank.org/curated/en/323311493396993758/pdf/final-report.pdf"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Philippines,YES,"The Philippines consistently publishes national antimicrobial resistance surveillance data related to pharmaceutical products through its Antimicrobial Resistance Surveillance Program (ARSP), including annual reports and contributions to international programs.[2][4][5]","https://pmc.ncbi.nlm.nih.gov/articles/PMC7264328/,https://www.nature.com/articles/s41467-020-16322-5,https://www.sanger.ac.uk/news_item/genomic-surveillance-of-antibiotic-resistance-in-the-philippines-established/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9220349/,https://pmc.ncbi.nlm.nih.gov/articles/PMC9831596/"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Cambodia,PARTIAL,"Cambodia officially accepts the ASEAN Common Technical Document (ACTD) format, not the ICH CTD format; however, there is some indication that ICH CTD might be accepted in practice, but this is not confirmed as regulatory policy[5].","https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://data.wahooas.org/tenders/uploads/attachment/document/357/CTD_En_Guidance_for_the_Preparation_of_Applications.pdf,https://www.ijdra.com/index.php/journal/article/view/318,https://www.efpia.eu/media/636610/ectd-white-paper_final-20-dec-21.pdf,https://dcvmn.org/wp-content/uploads/2019/03/dcvmn_singapore_actd_and_ich_ctd_comparison_mar2019_ida.pdf"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Cambodia,PARTIAL,"Cambodia has developed and begun implementing an online registration system for pharmaceutical product marketing authorization applications, but the available sources indicate the system was under development and planning for expansion as of 2019, without explicit confirmation of full, nationwide operational status as of 2025.[1][3][5]","https://www.ungm.org/Public/Notice/91693,https://www.epo.org/law-practice/legal-texts/official-journal/2018/02/a16.html,https://www.ungm.org/Public/Notice/68203,https://ustr.gov/sites/default/files/files/Press/Reports/2025NTE.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC6016570/"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Cambodia,NO,"Cambodia does not legally require acceptance of another ASEAN Member State’s cGMP certificate for pharmaceutical manufacturers; it specifically requires submission of a Certificate of GMP from the country of origin, not from another AMS, and there is no evidence of a legal mandate for automatic recognition or acceptance of cGMP certificates issued by other ASEAN countries.","https://certease.com/gmp-certification-in-cambodia/,https://asean.org/wp-content/uploads/images/2013/economic/iai/ASEAN%20Cosmetics%20Directive%20CLMV%20Workshop%20Feb%202013.pdf,https://andamanmed.com/regulatory-services/medical-device-registration/cambodia/,https://www.ncbi.nlm.nih.gov/books/NBK555744/,https://andamanmed.com/cambodia-medical-device-regulation/"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Cambodia,NO,"Cambodia generally follows WHO guidelines, which require long-term stability data at 30°C/75% RH for registration; stability data at 25°C/60% RH is not normally sufficient, even when supported by accelerated studies, unless specifically justified and approved by the national regulatory authority.","https://humiditycontrol.com/blog/what-is-stability-testing/,https://www.zamra.co.zm/wp-content/uploads/2023/05/Marketing-Authorisation-STABILITY-GUIDELINES.pdf,https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf,http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Cambodia,UNKNOWN,"There is no explicit evidence in the available sources that Cambodia officially allows or prohibits bracketing and matrixing study designs in pharmaceutical product stability testing; regulatory practices in many countries follow ICH guidelines, but Cambodia's specific stance is not stated in the retrieved information.","https://humiditycontrol.com/blog/what-is-stability-testing/,https://www.ema.europa.eu/en/ich-q1d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products-scientific-guideline,https://kymos.com/news/stability-testing-2024/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://www.labmanager.com/stability-testing-of-pharmaceuticals-procedures-and-best-practices-33944"
Requires halal certification for pharmaceutical products.,Cambodia,NO,"Cambodia does not require halal certification for pharmaceutical products; while it has a commission for halal certification focused on food and related products, there is no regulatory requirement mandating halal certification for pharmaceuticals.[1][3]","https://www.ccfdg.gov.kh/en/commission-committee/new-title-3/,https://ucsiso.com/halal-certification-importance-process-benefits-with-ucs/,https://www.efpia.eu/media/412591/efpia-positionpaper-on-halal_final_5-dec-2018.pdf,https://www.halaltimes.com/turkey-agrees-to-help-develop-cambodias-halal-industry/,https://ic-halal.com/industries/pharma/"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Cambodia,NO,There is no evidence in Cambodian law or recent regulatory guidance that specifically mandates the use of a 'red dot' symbol on prescription-only pharmaceutical products; neither the primary drug law nor regulatory or practitioner guidance mention such a requirement.[1][3],"https://cdc.gov.kh/wp-content/uploads/2022/04/Law-on-Drug-Management_full-text_961209.pdf,https://chicagounbound.uchicago.edu/cgi/viewcontent.cgi?article=2753&context=law_and_economics,https://www.tilleke.com/insights/cambodia-prepares-to-curb-illegal-advertising-of-health-products/15/,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC9508725/"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Cambodia,NO,"Cambodia does not target an average marketing authorization approval timeline of six months or less for pharmaceutical products; the typical approval time for generic medicines is around 7 months, with standard applications not meeting a six-month goal, though a fast-track process may approve within 3–4 months for additional fees[1][5].","https://core.ac.uk/download/599695768.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/,https://www.ijdra.com/index.php/journal/article/download/245/138,https://www.corrs.com.au/site-uploads/images/PDFs/Insights/article-IP-comparative-overview-of-distribution-and-marketing-of-drugs-across-asia-pacific.pdf,https://credevo.com/articles/2021/03/15/generic-drug-registration-process-in-cambodia/"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Cambodia,NO,"Cambodia does not impose hospital-only distribution restrictions for specific classes of antimicrobial pharmaceuticals; antibiotics remain widely available without prescription at both formal and informal outlets, and no evidence of legally enforced hospital-only restrictions was found in official policies or stewardship interventions.[2][5][4]","https://icars-global.org/projects/ams-cambodia/,https://pmc.ncbi.nlm.nih.gov/articles/PMC6768357/,https://www.ungm.org/Public/Notice/62030,https://pmc.ncbi.nlm.nih.gov/articles/PMC9121421/,https://pmc.ncbi.nlm.nih.gov/articles/PMC8210153/"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Cambodia,PARTIAL,"Cambodia has an established national AMR surveillance system and regularly collects AMR data through laboratory-based networks for both human health and foodborne pathogens, but publicly available, regularly published national surveillance reports specifically detailing pharmaceutical-related AMR data remain limited and insufficient according to recent reviews and surveillance analyses[1][3][5].","https://pubmed.ncbi.nlm.nih.gov/31176035/,https://ghsindex.org/wp-content/uploads/2021/12/Cambodia.pdf,https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1332423/full,https://pmc.ncbi.nlm.nih.gov/articles/PMC8315476/,https://www.fao.org/fao-who-codexalimentarius/news-and-events/news-details/hu/c/1733551/"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Singapore,YES,"Singapore accepts the ICH Common Technical Document (CTD) format for innovator pharmaceutical product registrations, as applications must be submitted in either the ICH CTD or ACTD format per Health Sciences Authority (HSA) guidelines[2][4].","https://www.efpia.eu/media/636610/ectd-white-paper_final-20-dec-21.pdf,https://www.hsa.gov.sg/docs/default-source/hprg-tpb/guidances/guidance-on-therapeutic-product-registration-in-singapore.pdf?sfvrsn=cd174383_52,https://www.extedo.com/blog/singapores-transition-to-ectd,https://www.artixio.com/post/pharmaceutical-regulations-and-registration-in-singapore,https://gandlscientific.com/knowledge-hub/the-implementation-of-ectd-in-singapore"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Singapore,YES,"Singapore provides a fully digital online submission portal—PRISM—for pharmaceutical product marketing authorization applications, requiring applicants to submit all necessary documentation electronically through this platform managed by the Health Sciences Authority (HSA)[1][4][5].","https://www.rginsight.com/registration-of-drug-product-in-singapore-2025,https://www.hsa.gov.sg/therapeutic-products/register/ectd-submissions,https://www.pacificbridgemedical.com/uncategorized/singapore-drug-registration-a-comprehensive-guide/,https://www.hsa.gov.sg/therapeutic-products/register/guides/new-drug/verification-evaluation,https://credevo.com/articles/2023/03/15/drug-registration-approval-process-in-singapore/"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Singapore,YES,"Singapore is legally required to recognize and accept the cGMP certificates issued by another ASEAN Member State’s Listed Inspection Service (LIS) under the ASEAN Mutual Recognition Arrangement (MRA) for GMP inspection, without duplicating inspection in each other's territory[2][5].","https://www.hsa.gov.sg/therapeutic-products/register/gmp-conformity-assessment,https://www.hsa.gov.sg/docs/default-source/hprg/regulatory-updates/update-on-asean-mra-gmp.PDF,https://www.hsa.gov.sg/cosmetic-products/good-manufacturing-practice,https://apac-asia.com/images/achievements/pdf/14th/23_Presentation%20from%20Li%20Lian%20Lim,%20HSA.pdf,https://apac-asia.com/images/achievements/pdf/14th/22_Presentation%20from%20Kim%20Mi%20Hng,%20NPRA.pdf"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Singapore,PARTIAL,"Singapore requires submission of long-term stability data, typically at 30°C/75% RH (ASEAN zone IVb), and generally does not accept 25°C/60% RH data unless fully justified; accelerated studies alone are not sufficient for approval[5][1].","https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf,https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products_en.pdf,http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf,https://database.ich.org/sites/default/files/Q1A(R2)%20Guideline.pdf,https://www.hsa.gov.sg/docs/default-source/hprg-tpb/guidances/guidance-on-therapeutic-product-registration-in-singapore.pdf?sfvrsn=cd174383_52"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Singapore,YES,"Singapore adopts the ASEAN Guideline on Stability Study of Drug Product, which aligns with ICH guidelines that allow for the use of bracketing and matrixing study designs in pharmaceutical product stability testing when scientifically justified, subject to regulatory review and acceptance[1][3][2].","https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf,https://aapsopen.springeropen.com/articles/10.1186/s41120-023-00078-5,https://www.ich.org/page/quality-guidelines,https://japsonline.com/admin/php/uploads/409_pdf.pdf,http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf"
Requires halal certification for pharmaceutical products.,Singapore,NO,Singapore does not require halal certification for pharmaceutical products; halal certification in Singapore is generally optional and not mandated for pharmaceuticals[3][5].,"https://halalwatch.us/everything-you-need-to-know-about-the-halal-pharmaceutical-industry/,https://www.ushalalcertification.com/halal-certification/halal-certification-guidelines/,https://certease.com/halal-certification-in-singapore/,https://halal4pharma.com/wp-content/uploads/2021/04/FAQ_Halal_Pharmaceutical.pdf,https://www.efpia.eu/media/412591/efpia-positionpaper-on-halal_final_5-dec-2018.pdf"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Singapore,NO,There is no evidence in authoritative Singapore health agency sources or regulations that specifically mandate a 'red dot' symbol on prescription-only pharmaceutical products.,"https://hpb.gov.sg/healthy-living/food-beverage/nutri-grade,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://www.hsa.gov.sg/therapeutic-products/advertisements,https://pmc.ncbi.nlm.nih.gov/articles/PMC6963657/,https://www.cnb.gov.sg/drug-information/drugs-and-inhalants"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Singapore,PARTIAL,"Singapore does not generally target an average MA approval timeline of six months or less for pharmaceutical products, but some expedited routes (such as the verification route) may allow for approval within 60–120 working days, while typical timelines for other routes are longer (120–270 working days or more)[3][1].","https://www.sapi.org.sg/wp-content/uploads/2019/01/Fostering-IP-and-Innovation-for-Biopharmaceuticals.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC9734413/,https://www.pacificbridgemedical.com/uncategorized/singapore-drug-registration-a-comprehensive-guide/,https://www.hsa.gov.sg/docs/default-source/hprg-tpb/guidances/guidance-on-therapeutic-product-registration-in-singapore.pdf?sfvrsn=cd174383_52,https://cirsci.org/wp-content/uploads/2020/02/CIRS-RD-Briefing-72-Trends-in-the-regulatory-landscape-Asia.pdf"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Singapore,NO,"There is no evidence that Singapore imposes hospital-only distribution restrictions for specific classes of antimicrobial pharmaceuticals; instead, antimicrobials are generally subject to prescription-only or controlled-access status, and national AMR efforts focus on surveillance and stewardship rather than restricting distribution to hospitals.[4][2][3]","https://www.ncid.sg/Health-Professionals/Pages/Antimicrobial-Resistance.aspx,https://pmc.ncbi.nlm.nih.gov/articles/PMC6963657/,https://www.ncid.sg/Health-Professionals/Documents/One%20Health%20Report%20on%20Antimicrobial%20Utilisation%20and%20Resistance%202021.pdf,https://www.hsa.gov.sg/announcements/reclassified-medicines/updates-on-reclassified-medicines,https://pmc.ncbi.nlm.nih.gov/articles/PMC6717780/"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Singapore,YES,"Singapore publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products, as evidenced by the publicly available 'One Health Report on Antimicrobial Utilisation and Resistance' and regular national surveillance reports that include data on antimicrobial sales, use, and resistance patterns across humans, animals, food, and the environment[1][2][5].","https://www.ncid.sg/Health-Professionals/Documents/One%20Health%20Report%20on%20Antimicrobial%20Utilisation%20and%20Resistance%202021.pdf,https://www.ncid.sg/Health-Professionals/Documents/One%20Health%20Report%20on%20Antimicrobial%20Utilisation%20and%20Resistance%202019.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC6963657/,https://pmc.ncbi.nlm.nih.gov/articles/PMC6717780/,https://www.asianfisheriessociety.org/publication/downloadfile.php?id=1332&file=Y0dSbUx6QTBPREF4TWpnd01ERTJNRGc0T1RVeU1ESXVjR1Jt"
Accepts the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for innovator pharmaceutical product registrations.,Malaysia,YES,"Malaysia accepts the ICH Common Technical Document (CTD) format for innovator pharmaceutical product registrations, as the NPRA requires the registration dossier to follow either the ICH CTD or the ASEAN Common Technical Dossier (ACTD) format.[1]","https://www.rginsight.com/registration-of-drug-product-in-malaysia-2025,https://gabi-journal.net/regulation-of-biologics-in-malaysia.html,https://ijprajournal.com/issue_dcp/A%20Review%20Article%20on%20the%20Common%20Technical%20Document%20CTD%20Regulatory%20Dossier.pdf,https://www.ijpcbs.com/articles/comparative-study-of-regulatory-requirementsfor-the-compilation-and-approval-of-dossieras-per-ctd-actd-and-ectd-formats.pdf,https://jgtps.com/admin/uploads/zhg3fT.pdf"
Provides a fully digital online submission portal for pharmaceutical product marketing authorization applications.,Malaysia,YES,"Malaysia provides a fully digital online submission portal (the NPRA QUEST3 system) for pharmaceutical product marketing authorization applications, as applicants are required to apply online and submit all necessary documentation through this platform.[1][3][4]","https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/malaysia-drug-registration-and-approval/,https://portal.mda.gov.my/index.php/announcement/1536-pengumuman-peralihan-kepada-proses-permohonan-pengkelasan-produk-secara-dalam-talian,https://conventuslaw.com/report/the-framework-of-pharmaceutical-companies-in-malaysia/,https://www.azmilaw.com/insights/the-legal-framework-of-pharmaceutical-companies-in-malaysia/,https://npra.gov.my"
Legally requires acceptance of another ASEAN Member State’s (AMS) Certificate of Good Manufacturing Practice (cGMP) for pharmaceutical manufacturers.,Malaysia,YES,"Malaysia is legally required to accept and recognize cGMP certificates and inspection reports issued by another ASEAN Member State’s Listed Inspection Services under the ASEAN Mutual Recognition Arrangement (MRA) for GMP Inspection, as implemented in Malaysian regulations and practice[1][4][5].","https://globalforum.diaglobal.org/issue/march-2021/harmonization-of-gmp-inspection-and-benefits-to-asean-economic-community/,https://npra.gov.my/easyarticles/images/users/1050/FAQs-Foreign-Inspection-Jan-2020.pdf,https://npra.gov.my/easyarticles/images/users/1133/2023%20Mar/Guidance-Document---Foreign-GMP-Inspection_9th-Edition.pdf,https://gabi-journal.net/a-review-of-international-initiatives-on-pharmaceutical-regulatory-reliance-and-recognition.html,https://www.npra.gov.my/index.php/en/regulation-basic.html"
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.,Malaysia,YES,"Malaysia permits stability data submission at 25°C/60% RH in accordance with ASEAN and NPRA guidelines, provided that accelerated stability data are also included to support shelf life as recommended in regional and international standards[1][5].","https://www.npra.gov.my/easyarticles/images/users/1153/drgd_appendices/APPENDIX-3-Guidelines-on-Registration-of-New-Drug-Products.pdf,https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf,https://credevo.com/articles/2022/10/05/drug-registration-in-malaysia-regulatory-process-requirements/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf,https://asean.org/wp-content/uploads/2021/08/ASEAN-Common-Technical-Requirements-ACTR.pdf"
Allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing.,Malaysia,YES,"Malaysia allows the use of bracketing and matrixing study designs in pharmaceutical product stability testing, as it adheres to ASEAN and ICH guidelines which support these approaches when scientifically justified[2][3].","https://www.artixio.com/post/pharmaceutical-regulations-and-registration-in-malaysia,https://apac-asia.com/images/achievements/pdf/8th/3_ATIM/2_Template%20from%20Malaysia.pdf,https://www.pacificbridgemedical.com/ufaq/what-are-the-requirements-for-stability-studies-in-drug-registration-in-malaysia/,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf,https://siip.ac.in/wp-content/uploads/2021/04/stability-testing.pdf"
Requires halal certification for pharmaceutical products.,Malaysia,NO,"Halal certification for pharmaceutical products in Malaysia is not mandatory, but is available for certain categories such as over-the-counter medicines, health supplements, and traditional medicines; prescription drugs containing scheduled poisons cannot be halal-certified under current regulations.","https://halalwatch.us/everything-you-need-to-know-about-the-halal-pharmaceutical-industry/,https://hrmars.com/papers_submitted/13210/halal-labelling-for-the-malaysian-pharmaceutical-products-a-legal-review.pdf,https://cyberjaya.edu.my/research-news/from-source-to-solution-the-halal-pharmaceutical-journey-in-malaysia,https://www.aseanbriefing.com/news/how-to-obtain-halal-certification-in-malaysia/,https://halalfoundation.org/insights/halal-pharmaceuticals-and-supplements-certification/"
Specifically mandates the use of a “red dot” symbol on prescription-only pharmaceutical products.,Malaysia,NO,Malaysia does not specifically mandate the use of a 'red dot' symbol on prescription-only pharmaceutical products; official NPRA drug labeling and registration guidelines make no mention of such a requirement in their latest documentation[1][5].,"https://www.npra.gov.my/images/Guidelines_Central/appendix/APPENDIX_9_LABELLING_REQUIREMENTS.pdf,http://www.tsmia.or.th/RTD2022/Self-CARER_e-book_final.pdf,https://prioocare.com/2025/05/22/kkm-product-verification-what-you-need-to-know/,https://www.guttmacher.org/sites/default/files/report_pdf/abortion-methodologies.pdf,https://www.npra.gov.my/easyarticles/images/users/1153/DRGD%20January%202024/Complete-Drug-Registration-Guidance-Document-DRGD-3rd-Edition-7th-Revision-January-2024.pdf"
Targets an average marketing authorization (MA) approval timeline of six months or less for pharmaceutical products.,Malaysia,NO,"Malaysia does not target an average marketing authorization approval timeline of six months or less; recent studies and regulatory briefings report average approval timelines for pharmaceutical products as approximately 400–515 calendar days (about 13–17 months), depending on product type and review pathway[2][5].","https://www.freyrsolutions.com/what-is-the-pharmaceutical-products-approval-process-in-malaysia,https://cirsci.org/wp-content/uploads/2020/05/Mohd-Sani-et-al-2020-Evaluation-of-Malaysia-regulatory-process-combined-with-correction.pdf,https://gabionline.net/policies-legislation/npra-malaysia-trials-new-timelines-for-variation-applications,https://japsonline.com/admin/php/uploads/4454_pdf.pdf,https://cirsci.org/wp-content/uploads/2020/02/CIRS-RD-Briefing-72-Trends-in-the-regulatory-landscape-Asia.pdf"
Imposes hospital-only distribution restrictions for certain classes of antimicrobial (AM) pharmaceutical products.,Malaysia,NO,"Malaysia does not impose hospital-only distribution restrictions for antimicrobial pharmaceuticals at the national policy level; instead, it regulates hospital prescribing through antimicrobial stewardship programs, including restrictive authorization in hospitals, but there is no evidence of a legal or regulatory hospital-only distribution mandate for AM products themselves.[1][5]","https://pmc.ncbi.nlm.nih.gov/articles/PMC5017119/,https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1381843/full,https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.718774/full,https://pmc.ncbi.nlm.nih.gov/articles/PMC9137524/,https://pmc.ncbi.nlm.nih.gov/articles/PMC7345343/"
Publishes national antimicrobial resistance (AMR) surveillance data related to pharmaceutical products.,Malaysia,YES,"Malaysia does publish national antimicrobial resistance (AMR) surveillance data, such as the National Antibiotic Resistance Surveillance Report (NSAR), which compiles antibiotic susceptibility testing results from hospitals nationwide for pharmaceutical products.[1][3][5]","https://library.nih.gov.my/e-doc/imr/nsar-2023.pdf,https://www.moh.gov.my/moh/resources/Penerbitan/Garis%20Panduan/Pengurusan%20KEsihatan%20&%20kawalan%20pykit/Malaysian_Action_Plan_on_Antimicrobial_Resistance_(MyAP-AMR)_2017-2021.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC10764260/,https://asean.org/wp-content/uploads/2023/02/Rapid-Assessment-of-the-Regulatory-Measures-in-Combating-Antimicrobial-Resistance-AMR-in-the-ASEAN-Region_-Feb-2023-OK-1.pdf,https://pmc.ncbi.nlm.nih.gov/articles/PMC8573254/"
